Hepatitis C : Drug Therapy : Gilead Successfully Completes Fourth Phase III Study "This morning Gilead announced that it has successfully wrapped up positive top-line data from its fourth and last Phase III study for sofosbuvir, putting the biotech on a short path to the FDA with what promises to be the first oral drug for hepatitis C."

 

To read more please visit: http://www.fiercebiotech.com/story/gilead-races-fda-after-hep-c-blockbuster-hopeful-scores-4th-win-phiii/2013-02-19?utm_medium=nl&utm_source=internal

 


]]> Tue, 19 Feb 2013 18:03:34 GMT